Transgender Health clinical trials at UCSD

3 in progress, 1 open to eligible people

Showing trials for

  • Androgen Effects on the Reproductive Neuroendocrine Axis, 2025 Version

    open to eligible females ages 18-35

    This research study investigates whether male-level exogenous androgens inhibit the reproductive neuroendocrine axis in otherwise healthy (non-PCOS) females.

    San Diego, California

  • Emtricitabine/Tenofovir Alafenamide Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate Pre-Exposure Prophylaxis (PrEP) levels in transgender-identifying or gender non-binary individuals taking versus not taking gender affirming hormone therapy. Subjects who have previously taken F/TDF as PrEP will continue with a fixed dose combination of daily oral F/TAF substituting for F/TDF. Subjects will receive the iTAB text messaging adherence reminders to provide personalized, automated text messages to support and monitor adherence that will vary by participant choice until 12 weeks after switching medication. This study will enroll 60 individuals to take F/TAF as PrEP for 48 weeks.

    San Diego, California

  • Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection

    Sorry, in progress, not accepting new patients

    The goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) in preventing HIV infection, in participants ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV-1 infection. The primary objective of this study is to evaluate the efficacy of LEN for HIV-1 PrEP in participants ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth at risk of HIV-1 infection.

    San Diego, California and other locations

Our lead scientists for Transgender Health research studies include .

Last updated: